

XIFAXAN (rifaximin) (non-preferred) PRIOR AUTHORIZATION FORM

Antibiotics, GI and Related Agents (including Xifaxan) and Quantity Limits/Daily Dose Limits prior authorization guidelines are accessible on the Department's Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION			
Beneficiary name:		Street address:	
Beneficiary ID#:		Suite #:	City/State/Zip:
DOB:		Phone:	Fax:

CLINICAL INFORMATION

Product requested: Xifaxan tablet	Strength: <input type="checkbox"/> 200 mg <input type="checkbox"/> 550 mg <input type="checkbox"/> _____	Quantity:	Refills:
Dose/directions: <input type="checkbox"/> 200 mg three times daily x 3 days <input type="checkbox"/> 550 mg three times daily x 14 days <input type="checkbox"/> 550 mg twice daily <input type="checkbox"/> other: _____			
Diagnosis (<i>submit documentation</i>):		Dx code (<i>required</i>):	

Initial requests complete sections applicable to beneficiary's diagnosis

1. Hepatic encephalopathy: Does the beneficiary have a history of trial and failure, contraindication, or intolerance of lactulose ?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation.</i>
2. Travelers' diarrhea: Does the beneficiary have a history of trial and failure, contraindication, or intolerance of the following? <input type="checkbox"/> azithromycin (Zithromax) <input type="checkbox"/> fluoroquinolones (e.g., ciprofloxacin, levofloxacin)	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of all medications tried and outcomes.</i>
3. Irritable bowel syndrome with diarrhea (IBS-D): Is Xifaxan being prescribed by, or in consultation with, a gastroenterologist?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of consultation, if applicable.</i>
4. IBS-D: Have other causes of chronic diarrhea been ruled out, such as inflammatory bowel disease, malabsorption syndromes, chronic infection, celiac disease, malignancy, etc.?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of differential diagnosis.</i>
5. IBS-D: Does the beneficiary have a history of trial and failure, contraindication, or intolerance of the following medications? <i>Check all that apply.</i> <input type="checkbox"/> anti-diarrheals (e.g., loperamide) <input type="checkbox"/> antispasmodics (e.g., dicyclomine)	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of all medications tried and outcomes.</i>
6. IBS-D: Did the beneficiary try and fail standard IBS-D dietary modifications (e.g., avoidance of lactose, gluten, and artificial sweeteners; low FODMAP diet)?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of dietary changes tried and outcomes.</i>
7. All other diagnoses: Submit medical literature supporting the use of Xifaxan for the beneficiary's diagnosis and all treatment regimens tried.		

RENEWAL requests

1. Irritable bowel syndrome with diarrhea (IBS-D): Was the beneficiary's previous treatment course with Xifaxan successful?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of clinical response.</i>
2. IBS-D: Have the beneficiary's symptoms of IBS-D recurred since the previous treatment course?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation.</i>
3. IBS-D: How many treatment courses of Xifaxan has the beneficiary had? <i>Submit documentation.</i>	<input type="checkbox"/> one <input type="checkbox"/> two <input type="checkbox"/> other: _____	

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.